(Who and) When should patients with obesity and impaired glucose regulation undergo metabolic surgery?
|
|
- Paul Walters
- 5 years ago
- Views:
Transcription
1 (Who and) When should patients with obesity and impaired glucose regulation undergo metabolic surgery? Alex Miras Senior Clinical Lecturer in Endocrinology
2 Disclosures Fractyl Novo Nordisk Astra Zeneka
3 Edmonton Obesity Staging System (EOSS) Stage 2 co-morbidity Stage 1 moderate moderate Stage 3 Stage 0 Obesity Stage 4 Sharma AM & Kushner RF, Int J Obes 2009
4 EOSS Predicts Mortality in NHANES III Padwal R, Sharma AM et al. CMAJ 2011
5 King s Obesity Staging Score Aasheim E et al, Clinical Obesity 2011
6 Diagrams of the four bariatric/metabolic operations currently in common clinical use. Francesco Rubino et al. Dia Care 2016;39:
7 Current situation Operate on <1% of eligible patients Constantly use BMI to base treatment decisions First come first served Treat healthy obese Treat patients with end-stage disease
8 London underground newspaper
9 NICE guidelines for the surgical therapy of obesity Revised 2014 BMI > 40 BMI > 35 + significant comorbidities BMI T2DM for < 10 years
10 Weight loss Sjostrom L et al, JAMA 2014;311(22)
11 Bariatric Surgery and Long-term Cardiovascular Events
12 Bariatric Surgery and Long-term Cardiovascular Events
13 NBSR - 5 year effects of surgery Miras and Welbourn et al, unpublished data
14 Suggestions Stop using BMI cut offs - keep 30 (or even lower) Define what is a significant comorbidity Establish which comorbidity is improved by surgery in a cost effective manner Compare the cost effectiveness of treating comorbidities Establish predictive markers of comorbidity resolution Healthy obese will have to go to the back of the queue
15 Moving from weigh to sugar Dixon 2008 JAMA Mingrone 2012 NEJM Schauer 2012, 2014 NEJM
16 NICE guidelines for the surgical therapy of obesity Revised 2014 BMI > 40 BMI > 35 + significant comorbidities BMI T2DM for < 10 years
17 NICE guidelines for the therapy of T2DM Type 2 diabetes in adults: management, NICE guideline NG28 (December 2015)
18 HbA1c after metabolic surgery compared with medical treatments in published RCTs Among the RCTs, the most common predictors of diabetes remission included: duration of diabetes requirement for insulin disease status (HbA 1c ) Philip R. Schauer et al. Dia Care 2016;39:
19 Forest plots from a systematic review and meta-analysis of all published articles reporting T2DM remission rates following bariatric/metabolic surgery. BMI<35 Remission 72% BMI 35 Remission 71% David E. Cummings, and Ricardo V. Cohen Dia Care 2016;39:
20 Algorithm for the treatment of T2DM, as recommended by DSS-II voting delegates Francesco Rubino et al. Dia Care 2016;39:
21 Diabetes Remission in the SOS Sjostrom L et al, JAMA 2014;311(22)
22 Predictors of remission in the SOS Duration of diabetes Weight change at 2 years Not BMI Sjostrom L et al, JAMA 2014;311(22)
23 Microvascular complications Sjostrom L et al, JAMA 2014;311(22)
24 Macrovascular complications Sjostrom L et al, JAMA 2014;311(22)
25 Predictors of micro and macro-vascular complications Diabetes < 1 year Diabetes 4 years Sjostrom L et al, JAMA 2014;311(22)
26 Prevention of diabetes SOS study Carlsson LM at al, NEJM 2012
27 Reduction in microvascular complications A: normal glycaemia B: Prediabetes C: New T2DM D: Established T2DM Mingrone 2012 NEJM Carlsson et al, Lancet D&E 2017
28 Conclusion so far Data say: We should be operating on patients with pre-diabetes or as early as possible in their diagnosis of T2DM In practice: Really?
29 Liraglutide and Body Weight Pi-Sunyer X et al. N Engl J Med 2015;373:11-22
30 Liraglutide and glycaemia Pi-Sunyer X et al. N Engl J Med 2015;373:11-22
31 Liraglutide for CV events in diabetes Marso SP et al. N Engl J Med 2016.
32 Empagliflozin: Cardiovascular Outcomes and Death Zinman B et al. N Engl J Med DOI: /NEJMoa
33 Empagliflozin and kidneys Wanner C et al. N Engl J Med 2016;375:
34 Suggestions If the patient has multiple comorbidities and also happen to have pre-diabetes or early diabetes - operate (obesity surgery) If the patient just has T2DM - work with non-surgical treatments When you see insulin coming - operate, prioritise (metabolic surgery) In advanced T2DM (when you are stuck) - still operate but expect less; do not prioritise
35 Acknowledgements Imperial College London Steve Bloom Tricia Tan Anna Kamocka Belen Pevida Madawi Aldhwayan Harvinder Chahal Samantha Scholtz Ahmed Ahmed Sanjay Purkayastha Krishna Moorthy Julian Teare University of Dublin Carel W le Roux Neil Docherty University of Surrey Margot Umpleby Barbara Fielding Fariba Shojaee-Moradie Nicola Jackson Florida State University Alan C Spector King s College London Francesco Rubino Ameet Patel Simon Aylwin Royce Vincent King Saud University, Saudi Arabia Ghalia Abdeen University of Zurich Marco Bueter University of Wurzburg Florian Seyfried
36 Morbidity and weight loss sensitivity or resistance Metabolic Ventilatory Reproductive CV risk Perceived health status Eating behaviour % weight loss to improve morbidity ADL / QoL Anxiety / depression Body Image dysphoria Economic cost Aylwin 2005
37 Liraglutide and the liver Armstrong et al, Lancet D&E 2016
38 Targeting the Kidney Chao EC, et al. Nat Rev Drug Discovery. 2010;9:
Bariatric surgery from morbid obesity to obese morbidity
Bariatric surgery from morbid obesity to obese morbidity Dr Alexander Miras MRC Clinical Research Fellow Imperial Weight Centre - Charing Cross Hospital Metabolic Imaging Group - Hammersmith Hospital What
More informationObesity and T2DM trials
Obesity and T2DM trials Dr Alexander Miras Senior Clinical Lecturer Endocrinology Look AHEAD NEJM 2013 LOOK AHEAD trial - weight loss for diabetes with and without cardiovascular disease Look AHEAD NEJM
More informationObesity Who is suitable for surgery? Professor Rob Andrews University of Exeter / Taunton NHS trust
Obesity Who is suitable for surgery? Professor Rob Andrews University of Exeter / Taunton NHS trust Investigator on BYBAND study Conflict of interest 3 Diet and Exercise studies (ACTID, EXTOD, STAMP2)
More informationHow the gut talks to the brain: future perspectives of obesity management
How the gut talks to the brain: future perspectives of obesity management Carel le Roux Co-Director of the Metabolic Medicine Group, University College Dublin Conflict of interest AstraZeneca Boehringer
More informationClinical Staging for Obesity. Raj Padwal Clinical Pharmacology and General Internal Medicine University of Alberta
Clinical Staging for Obesity Raj Padwal Clinical Pharmacology and General Internal Medicine University of Alberta Disclosures Funding: CIHR, Heart and Stroke Foundation of Canada, University Hospital Foundation.
More informationPage 2: Baker IDI. Page 4: Baker IDI. Global & Regional Obesity. High income English speaking Light Blue. Global & Regional Severe obesity
Metabolic Update Patients selection and choice of procedure Professor John B Dixon MBBS, FRACGP, FRCP Edin, PhD NHMRC Senior Research Fellow Head of Clinical Obesity Research, Baker IDI Heart and Diabetes
More informationPage 2: Baker IDI. Page 4: Baker IDI. Global & Regional Obesity. High income English speaking Light Blue. Global & Regional Severe obesity
Metabolic Surgery Update Patients selection and choice of procedure Professor John B Dixon MBBS, FRACGP, FRCP Edin, PhD NHMRC Senior Research Fellow Head of Clinical Obesity Research, Baker IDI Heart and
More information6/10/2016. Bariatric Surgery: Impact on Diabetes and CVD Risk. Disclosures BARIATRIC PROCEDURES
Bariatric Surgery: Impact on Diabetes and CVD Risk Anthony M Gonzalez, MD, FACS, FASMBS Medical Director Bariatric Surgery, South Miami Hospital Chief of Surgery, Baptist Hospital of Miami Associate Professor
More informationBariatric Surgery vs. Intensive Medical Therapy in Obese Diabetic Patients: 3-Year Outcomes
Bariatric Surgery vs. Intensive Medical Therapy in Obese Diabetic Patients: 3-Year Outcomes Results of the STAMPEDE Trial Philip R Schauer, Deepak L Bhatt, John P Kirwan, Kathy Wolski, Stacy A Brethauer,
More informationEndocrinologist Sweetgrass Endocrinology
Endocrinologist Sweetgrass Endocrinology Sanders, Cummings Ask Justice Department to Investigate Insulin Prices The Department of Justice and the FTC are asked to investigate whether Lilly, Novo Nordisk,
More informationType 2 diabetes and metabolic surgery:
Type 2 diabetes and metabolic surgery: Shouldn't we call it again again bariatric? Josep Vidal Obesity Unit. Endocrinology and Nutrition Department Hospital Clínic, University of Barcelona (Spain) What
More informationCurrent Trends in Bariatric Surgery
Current Trends in Bariatric Surgery 9.28.2017 Abraham Krikhely, MD, FACS, FASMBS Assistant Professor of Surgery, CUMC Center of Minimal Access, Metabolic and Weight Loss Surgery Outline Why consider surgery
More informationUnderstanding Clinical Assessment Using The Edmonton Obesity Staging System
Understanding Clinical Assessment Using The Edmonton Obesity Staging System Arya M Sharma, MD. PhD, FRCPC Research Chair for Obesity Research & Management University of Alberta Medical Director Alberta
More informationEffect of Bariatric Surgery on Cardio-Metabolic Outcomes
Effect of Bariatric Surgery on Cardio-Metabolic Outcomes Disclosure Research support from Bariatric Advantage (supplements donated for research study) Anne Schafer, MD Associate Professor of Medicine and
More informationOther Ways to Achieve Metabolic Control
Other Ways to Achieve Metabolic Control Nestor de la Cruz- Muñoz, MD, FACS Associate Professor of Clinical Surgery Chief, Division of Laparoendoscopic and Bariatric Surgery DeWitt Daughtry Family Department
More informationType 2 diabetes and metabolic surgery:
Type 2 diabetes and metabolic surgery: Shouldn't we call it again Surgery for Type 2 DM again bariatric? Is it Metabolic or Bariatric surgery? Josep Vidal Obesity Unit. Endocrinology and Nutrition Department
More informationDiabesita : integrazione tra terapia medica e terapia chirurgica Prof. Monica Nannipieri Dip. Medicina Clinica e Sperimentale Università di Pisa
Diabesita : integrazione tra terapia medica e terapia chirurgica Prof. Monica Nannipieri Dip. Medicina Clinica e Sperimentale Università di Pisa Dichiaro di non avere alcun conflitto d interesse Medical
More informationWhy Do We Care About Prediabetes?
Why Do We Care About Prediabetes? Complications of Diabetes Diabetic Retinopathy Leading cause of blindness in adults 1,2 Diabetic Nephropathy Leading cause of Kidney failure Stroke 2- to 4-fold increase
More informationWhy is Earlier and More Aggressive Treatment of T2 Diabetes Better?
Blood glucose (mmol/l) Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Disclosures Dr Kennedy has provided CME, been on advisory boards or received travel or conference support from:
More informationMr Jon Morrow. General Surgeon Department of Bariatric Surgery Middlemore Hospital. 16:55-17:10 Why Bariatric Surgery?
Mr Jon Morrow General Surgeon Department of Bariatric Surgery Middlemore Hospital 16:55-17:10 Why Bariatric Surgery? Why Bariatric Surgery? Jon Morrow Bariatric Surgery Misconceptions Surgery is a cop
More informationPreliminary Timetable (subject to change)
Monday, September 28, 2015 08:00-08:30 Opening Ceremony 08:30-09:00 World Congress and DSS: Rationale and Methods 08:30-08:45 08:45-09:00 09:00-10:00 09:00-09:20 09:20-09:40 09:40-10:00 World Congress
More informationAsia-Pacific Workshop
Asia-Pacific Workshop Metabolic Surgery for Type 2 Diabetes REGISTRATION DISCOUNTED FOR MEMBERS OF IFSO FEBRUARY 6-7 2012 $280. 00 USD UNTIL DEC 15 TH NOTE: Registration fee increases to $380 after Dec.
More informationNew Paradigms of Type 2 Diabetes. From:
New Paradigms of Type 2 Diabetes From: www.nusi.org Presenter Disclosure Presenters Jason Fung Relationships with commercial interests: Grants/Research Support: None Grants/Speakers Bureau/Honoraria: Consulting
More informationUpdate on Diabetes Canadian Society of Internal Medicine Oct 11, 2018
https://www.australiawidefirstaid.com.au/what-is-diabetes/ Update on Diabetes Canadian Society of Internal Medicine Oct 11, 2018 Praveena Sivapalan MD, FRCPC Division of General Internal Medicine, University
More informationPROTEZIONE DAL DANNO RENALE NEL DIABETE TIPO 2: RUOLO DEI NUOVI FARMACI. Massimo Boemi UOC Malattie Metaboliche e Diabetologia IRCCS INRCA Ancona
PROTEZIONE DAL DANNO RENALE NEL DIABETE TIPO 2: RUOLO DEI NUOVI FARMACI Massimo Boemi UOC Malattie Metaboliche e Diabetologia IRCCS INRCA Ancona Disclosure Dr Massimo Boemi has been granted as speaker
More informationMetabolic Surgery for Type 2 Diabetes - Window into Pathophysiology-
Metabolic Surgery for Type 2 Diabetes - Window into Pathophysiology- Prof. Francesco Rubino, MD Chair of Bariatric and Metabolic Surgery King's College London London, UK September 15, 2014 DISCLOSURE SLIDE
More informationImpact of bariatric surgery on the management of type 2 diabetes mellitus in Singapore
Singapore Med J 2013; 54(7): 382-386 doi: 10.11622/smedj.2013138 Impact of bariatric surgery on the management of type 2 diabetes mellitus in Singapore Phong Ching Lee 1,3, MBChB, MRCP, Kwang Wei Tham
More informationBariatric Surgery Work Up, Patient Selection and Follow Up
Bariatric Surgery Work Up, Patient Selection and Follow Up A/Professor Tania Markovic Metabolism & Obesity Services, RPAH Boden Institute of Obesity, Nutrition, Exercise & Eating Disorders SLHD Bariatric
More informationWhat s the Goal? Individualizing Glycemic Targets. Matthew Freeby M.D. December 3 rd, 2016
What s the Goal? Individualizing Glycemic Targets Matthew Freeby M.D. December 3 rd, 2016 Diabetes Mellitus: Complications and Co-Morbid Conditions Retinopathy Between 2005-2008, 28.5% of patients with
More informationPrimary Outcome Results of DiRECT the Diabetes REmission Clinical Trial
Finding a practical management solution for T2DM, in primary care Primary Outcome Results of DiRECT the Diabetes REmission Clinical Trial Mike Lean, Roy Taylor, and the DiRECT Team IDF Abu Dhabi, December
More informationUpdate in Diabetes Care. Exercise and Bariatric Surgery. Ted Adams, PhD, MPH Intermountain LiVe Well Center Salt Lake October 6, 2017
Update in Diabetes Care Exercise and Bariatric Surgery Ted Adams, PhD, MPH Intermountain LiVe Well Center Salt Lake October 6, 2017 There is no drug in current or perspective use that holds as much promise
More informationObesity Management in Patients with Diabetes Jamy D. Ard, MD Sunday, February 11, :15 a.m. 11:00 a.m.
Obesity Management in Patients with Diabetes Jamy D. Ard, MD Sunday, February 11, 2018 10:15 a.m. 11:00 a.m. Type 2 diabetes mellitus (T2DM) is closely associated with obesity, primarily through the link
More informationSurgery recommendations based on BMI and glycemic control
Surgery recommendations based on BMI and glycemic control BMI (kg/m2) in type 2 diabetes patients Glycemic control Surgery guidelines 40+ (37.5+ in Asian Americans) Controlled or uncontrolled Recommended
More informationDr Matthew Coghlan Novo Nordisk
Dr Matthew Coghlan Novo Nordisk Preventing diabetes and its complications Matthew Coghlan PhD Senior Director Search & Evaluation Global Drug Discovery Novo Nordisk A/S Obesity rates worldwide are increasing
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More informationType 2 diabetes remission following gastric bypass: does diarem stand the test of time?
Surg Endosc (2017) 31:538 542 DOI 10.1007/s00464-016-4964-0 and Other Interventional Techniques Type 2 diabetes remission following gastric bypass: does diarem stand the test of time? J. Hunter Mehaffey
More informationGoals for Medical Treatment in Obesity and Prediabetes: Improving Outcomes
Goals for Medical Treatment in Obesity and Prediabetes: Improving Outcomes Leigh Perreault, MD Associate Professor of Medicine Endocrinology, Metabolism and Diabetes University of Colorado Anschutz Medical
More informationDiabetes new challenges, new agents, new order
Diabetes new challenges, new agents, new order Ken Earle St Georges University Hospitals NHS Foundation Trust Overview Cardiovascular disease unmet needs Treating evident and residual risk Integrating
More informationPharmacotherapy IV: Liraglutide for Chronic Weight Management SARAH CAWSEY MD, FRCPC 2 ND ANNUAL OBESITY UPDATE SEPTEMBER 22, 2018
Pharmacotherapy IV: Liraglutide for Chronic Weight Management SARAH CAWSEY MD, FRCPC 2 ND ANNUAL OBESITY UPDATE SEPTEMBER 22, 2018 Disclosures Faculty Assistant Clinical Professor, Department of Medicine,
More informationLa lezione dei trials di safety cardiovascolare. Edoardo Mannucci
La lezione dei trials di safety cardiovascolare Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca, Boehringer
More informationBariatric Surgery Update
Friday General Session Bariatric Surgery Update Alex Perez, MD Chief, Division of Minimally Invasive and Foregut Surgery James E. Thompson, MD Family Distinguished Professor in Surgical Simulation Co Director,
More informationSLEEVEPASS RCT: SLEEVE vs. bypass 5-year results
SLEEVEPASS RCT: SLEEVE vs. bypass 5-year results Thun 30.11.2018 Paulina Salminen MD, PhD, Professor of Surgery Turku University Hospital, Turku, Finland SLEEVEPASS trial PI Disclosures Lecture fees: Merck,
More informationWhat s new in diabetes care? Connect and Learn April 13, 2018 Tess Montada-Atin NP-Adult, CDE
What s new in diabetes care? Connect and Learn April 13, 2018 Tess Montada-Atin NP-Adult, CDE (IDF, 2017) https://www.diabetes.ca News flash: 5 types of diabetes? 5 clusters based on: patient characteristics
More informationDiabetes and Heart Failure: The Role of SGLT2 Inhibitors
22 nd Annual Heart Failure 2018 Symposium Diabetes and Heart Failure: The Role of SGLT2 Inhibitors Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationFaculty/Presenter Disclosure
Weight loss & Obesity WHAT S NEW & EXCITING? Tina Korownyk Dept of Family Medicine, UofA Faculty/Presenter Disclosure Faculty/Presenter: Tina Korownyk Relationships with commercial interests: None 1 Drowning
More informationDisclosures OBESITY. Overview. Obesity: Definition. Prevalence of Obesity is Rising. Obesity as a Risk Factor. None
Disclosures None OBESITY Florencia Halperin, M.D. Medical Director, Program for Management Brigham and Women s Hospital Instructor in Medicine, Harvard Medical School Overview Obesity: Definition Definition
More informationOBESITY 2008: DIET, EXERCISE, DRUGS, AND SURGERY
OBESITY 2008: DIET, EXERCISE, DRUGS, AND SURGERY Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest CLASSIFICATION OF OVERWEIGHT
More informationBariatric Surgery Update
Bariatric Surgery Update Alexander Perez, MD, FACS Professor of Surgery Chief, Division Minimally Invasive and Foregut Surgery Speaker Disclosure Dr. Perez has disclosed that the has no actual or potential
More informationDISCLOSURE STATEMENT
Challenging Cases in Obesity Management Jonathan Q. Purnell, MD Knight Cardiovascular Institute Division of Endocrinology Oregon Health & Science University DISCLOSURE STATEMENT Speaker: Jonathan Q. Purnell,
More informationCANVAS Program Independent commentary
CANVAS Program Independent commentary Cliff Bailey Aston University, Birmingham, UK 2017 Disclosures and disclaimers Clifford J Bailey CJB has attended advisory boards, undertaken ad hoc consultancy, received
More informationTreating Type 2 Diabetes by Treating Obesity. Vijaya Surampudi, MD, MS Assistant Professor of Medicine Center for Human Nutrition
Treating Type 2 Diabetes by Treating Obesity Vijaya Surampudi, MD, MS Assistant Professor of Medicine Center for Human Nutrition 2 Center Stage Obesity is currently an epidemic in the United States, with
More informationHealth is Not Measured in Pounds
Health is Not Measured in Pounds Arya M Sharma, MD. PhD, FRCPC Research Chair for Obesity Research & Management University of Alberta Medical Director Alberta Provincial Obesity Program Edmonton, AB, Canada
More informationIMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS
IMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS Dr Bidhu Mohapatra, MBBS, MD, FRACP Consultant Physician Endocrinology and General Medicine Introduction 382 million people affected by diabetes
More information3. Metabolic Surgery and Control of Type 2 Diabetes
3. Metabolic Surgery and Control of Type 2 Diabetes Philip R. Schauer, MD Shai M. Eldar, MD Helen M. Heneghan, MD Stacy A. Brethauer, MD The rising prevalence of obesity, coupled with disappointing results
More informationDiabetes Day for Primary Care Clinicians Advances in Diabetes Care
Diabetes Day for Primary Care Clinicians Advances in Diabetes Care Elliot Sternthal, MD, FACP, FACE Chair New England AACE Diabetes Day Planning Committee Welcome and Introduction This presentation will:
More informationMedical therapy advances London/Manchester RCP February/June 2016
Medical therapy advances London/Manchester RCP February/June 2016 Advances in medical therapies for diabetes mellitus Duality of interest: The speaker or institutions with which he is associated has received
More informationBariatric surgery: Impact on Co-morbidities and Weight Loss Expectations ALIYAH KANJI, MD FRCSC MIS AND BARIATRIC SURGERY SEPTEMBER 22, 2018
Bariatric surgery: Impact on Co-morbidities and Weight Loss Expectations ALIYAH KANJI, MD FRCSC MIS AND BARIATRIC SURGERY SEPTEMBER 22, 2018 Disclosures None Objectives Review expected weight loss from
More informationADVANCE post trial ObservatioNal Study
Hot Topics in Diabetes 50 th EASD, Vienna 2014 ADVANCE post trial ObservatioNal Study Sophia Zoungas The George Institute The University of Sydney Rationale and Study Design Sophia Zoungas The George Institute
More informationDu gusts is megl che one. Edoardo Mannucci
Du gusts is megl che one Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca, Boehringer Ingelheim, Eli
More informationGlucose Control and Prevention of Cardiovascular Disease
Glucose Control and Prevention of Cardiovascular Disease Dr Peter A Senior BMedSci MBBS PhD FRCP(E) Associate Professor, Director Division of Endocrinology, University of Alberta Diabetes Update+, March
More informationIn compliance with the accrediting board policies, the American Diabetes Association requires the following disclosure to the participants:
In compliance with the accrediting board policies, the American Diabetes Association requires the following disclosure to the participants: Entity Activity Financial Consideration Comments Novo Nordisk
More informationCurrent Updates & Challenges In Managing Diabetes in CVD
Current Updates & Challenges In Managing Diabetes in CVD Preventive Cardiovascular Conference 2016 Instituit Jantung Negara 12 th November 2016 Nor Azmi Kamaruddin Diabetes Clinic Department of Medicine
More informationClinical Practice Guidelines for the Metabolic and Nonsurgical Support of the Bariatric Surgery Patient-2014 Update
Clinical Practice Guidelines for the Metabolic and Nonsurgical Support of the Bariatric Surgery Patient-2014 Update 1.Introduction Obesity continues to be a major public health problem in Belgium, with
More informationWeighty Issues in Type 2 diabetes
Weighty Issues in Type 2 diabetes Joseph Proietto University of Melbourne Department of Medicine and Department of Diabetes and Endocrinology Austin Health j.proietto@unimelb.edu.au Dennis Wilson 2 Declaration
More informationCardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes
Biomarkers 2018 Cardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationPreventing Serious Health Consequences of Type 2 Diabetes
Preventing Serious Health Consequences of Type 2 Diabetes The Evidence Hertzel C. Gerstein MD MSc FRCPC Professor and Population Health Institute Chair in Diabetes Research McMaster University and Hamilton
More informationLATE BREAKING STUDIES IN DM AND CAD. Will this change the guidelines?
LATE BREAKING STUDIES IN DM AND CAD Will this change the guidelines? Objectives 1. Discuss current guidelines for prevention of CHD in diabetes. 2. Discuss the FDA Guidance for Industry regarding evaluating
More informationNon-alcoholic fatty liver disease: time to take note and manage. Philip Newsome Professor of Hepatology & Director of Centre for Liver Research
Non-alcoholic fatty liver disease: time to take note and manage Philip Newsome Professor of Hepatology & Director of Centre for Liver Research Disclosures Consultancy, Co-ordinating Investigator roles
More informationWelche Operation für welchen Patienten: Sleeve, Bypass oder?
Welche Operation für welchen Patienten: Sleeve, Bypass oder?? Prof. Dr. med. Ralph Peterli Stv. Chefarzt Clarunis Leiter Forschungsplattform Viszeralchirurgie und bariatrisches Referenzzentrum Präsident
More informationLearning and Earning with Gateway Professional Education CME/CEU Webinar Series. Diabetes Update July 6, :00pm 1:00pm
Learning and Earning with Gateway Professional Education CME/CEU Webinar Series Diabetes Update July 6, 2017 12:00pm 1:00pm Jennifer Pennock Holst, MD Endocrinology, Diabetes & Metabolism AHN Center for
More informationAttitudes and Concerns of Diabetic Patients towards Bariatric Surgery as Treatment of Diabetes
495 Original Article Attitudes and Concerns of Diabetic Patients towards Bariatric Surgery as Treatment of Diabetes Hui Wen Chua, 1 MBBS (Singapore), MRCS (Ed), Hui Jun Zhou, 2 MBBS, MSc, PhD, Chin Meng
More informationBARIATRIC SURGERY AND TYPE 2 DIABETES MELLITUS
BARIATRIC SURGERY AND TYPE 2 DIABETES MELLITUS George Vl Valsamakis European Scope Fellow Obesity Visiting iti Associate Prof Warwick Medical School Diabetes is an increasing healthcare epidemic throughout
More information17 th July 2016 Chennai, Tamil Nadu India
17 th July 2016 Chennai, Tamil Nadu India "Dia League was held at Chennai, Tamil Nadu, India. The CME was organized by of Asian Society of Continuing Medical Education. The sole objective of the CME was
More informationDiabetes and Weight in Comparative Studies of Bariatric Surgery vs Conventional Medical Therapy: A Systematic Review and Meta-Analysis
OBES SURG (2014) 24:437 455 DOI 10.1007/s11695-013-1160-3 REVIEW ARTICLE Diabetes and Weight in Comparative Studies of Bariatric Surgery vs Conventional Medical Therapy: A Systematic Review and Meta-Analysis
More informationBeyond A1C. Non-glycemic Effects of GLP-1 Receptor Agonists. Olga Astapova MD, PhD Luis Chavez MD URMC Endocrinology Fellows
Beyond A1C Non-glycemic Effects of GLP-1 Receptor Agonists Olga Astapova MD, PhD Luis Chavez MD URMC Endocrinology Fellows Disclosures No conflicts of interest. Learning Objectives 1. Understand the physiological
More informationNew insights in metabolic surgery
New insights in metabolic surgery G.Hubens 11th Starters Package Who would have thought it? An operation proves to be the most effective therapy for adult onset diabetes W Pories 1995 222: 339-350 KEY
More informationGlycemic control a matter of life and death
Glycemic control a matter of life and death Linda Garcia Mellbin MD PhD Specialist in Cardiology & Internal medicine Dep of Cardiology Karolinska University Hospital /Karolinska Institutet Mortality (%)
More informationOBESITY IN TYPE 2 DIABETES
OBESITY IN TYPE 2 DIABETES Ashley Crowl, PharmD, BCACP Assistant Professor University of Kansas Objectives Review how to manage obesity in patients with type-2 diabetes mellitus Compare antiobesity agents
More informationAppetite, Glycemia and Entero-Insular Hormone Responses Differ Between Oral, Gastric-Remnant and Duodenal Administration of a Mixed Meal Test After
Appetite, Glycemia and Entero-Insular Hormone Responses Differ Between Oral, Gastric-Remnant and Duodenal Administration of a Mixed Meal Test After Roux-en-Y Gastric Bypass June 2018 How a surgical complication
More informationBNORC: Contribution over 25 years to evidence on obesity and cancer
BNORC: Contribution over 25 years to evidence on obesity and cancer Graham A Colditz, MD DrPH Niess-Gain Professor Chief, Boston July 10, 2017 https://tinyurl.com/ybmnqorq Economic costs of diabetes:
More informationInitiating Insulin in Primary Care for Type 2 Diabetes Mellitus. Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre
Initiating Insulin in Primary Care for Type 2 Diabetes Mellitus Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre Outline How big is the problem? Natural progression of type 2 diabetes What
More informationA Guidance Statement from the American College of Physicians
Hemoglobin A1c Targets for Glycemic Control with Pharmacologic Therapy in Non-Pregnant Adults with Type 2 Diabetes Mellitus: A Guidance Statement from the American College of Physicians Timothy J. Wilt,
More informationTop 5 (Topics) Papers In GIM Rocky Mountain ACP Internal Medicine Meeting Raj Padwal November 13, 2008
Top 5 (Topics) Papers In GIM 2008 Rocky Mountain ACP Internal Medicine Meeting Raj Padwal November 13, 2008 Methods Searched ACPJC/EBM, TOC of top medical journals, MEDSCAPE Best Evidence, consultation
More informationOverview T2DM medications. Winnie Ho
Overview T2DM medications Winnie Ho Diabetes in Australia 1.7 million Australians with diabetes, of these 85% have T2DM 2-fold excess risk CV death in patients with diabetes Risk factor for progression
More informationSubstantial Decrease in Comorbidity 5 Years After Gastric Bypass
Substantial Decrease in Comorbidity 5 Years After Gastric Bypass A Population-based Study From the Scandinavian Obesity Surgery Registry Sundbom, Magnus; Hedberg, Jakob; Marsk, Richard; Boman, Lars; Bylund,
More informationTerapia con agonisti GLP1 e outcome cardiovascolare. Edoardo Mannucci
Terapia con agonisti GLP e outcome cardiovascolare Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca,
More informationCardiovascular Benefits of Two Classes of Antihyperglycemic Medications
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017
More informationChairman s Rounds, 02/15/2011
Chairman s Rounds, 02/15/2011 Edward Lipkin, MD Associate Professor, Department of Medicine Division of Metabolism, Endocrinology and Nutrition University of Washington Predictive factors in patient s
More informationMicrovascular Complications in Diabetes:
Microvascular Complications in Diabetes: Perspectives on Glycemic Control to Prevent Microvascular Complications Discussion Outline: Glycemia and Microvascular Compliations Clinical Trials - A Brief History
More informationFive Things a Family Physician Needs to Know about Baritric Surgery.
Five Things a Family Physician Needs to Know about Baritric Surgery. Dr. J Kenneth Reed MD FRCS(C) Guelph General Bariatric Centre of Excellence May 2014 Five Things to Know About Bariatric Surgery Presenter
More informationT2 Diabetes in Sep-16. Stephen Leow Disclosures. Why do we treat diabetes? Agenda. Targets
Stephen Leow Disclosures I have received honoraria, sat on the advisory boards or received grants from Novo Nordisk, Sanofi Aventis, Eli Lilly, Boehringer Ingleheim, Jansenn Cilag, Mundipharma, BioCSL,
More informationCase Report Off-Label Use of Liraglutide in the Management of a Pediatric Patient with Type 2 Diabetes Mellitus
Case Reports in Pediatrics Volume 2013, Article ID 703925, 4 pages http://dx.doi.org/10.1155/2013/703925 Case Report Off-Label Use of Liraglutide in the Management of a Pediatric Patient with Type 2 Diabetes
More informationCan Treating Diabetes with SGLT2 inhibitors Prevent Heart Failure?
UCSD Hawaii 2017 Symposium Can Treating Diabetes with SGLT2 inhibitors Prevent Heart Failure? Gregg C. Fonarow, MD, FACC, FAHA Elliot Corday Professor of Cardiovascular Medicine UCLA Division of Cardiology
More informationCan We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists
Can We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists Robert R. Henry, MD Professor of Medicine University of California, San Diego Relevant Conflict
More informationKey points Obesity is an increasing problem with rates continuing to rise Treatment for OSAHS is poorly tolerated but surgical weight loss has good
Key points Obesity is an increasing problem with rates continuing to rise Treatment for OSAHS is poorly tolerated but surgical weight loss has good long-term results has been shown to improve many of the
More informationThe Flozins Quest for Clarity?
The Flozins Quest for Clarity? Choosing Wisely with Academic Detailing 2018 ARE THEY THE REAL DEAL Disclosure statements The Academic Detailing Service is operated by Dalhousie Continuing Professional
More informationClinical Relevance of Blood Pressure Lowering Effect of Modern Antidiabetic Drugs
Clinical Relevance of Blood Pressure Lowering Effect of Modern Antidiabetic Drugs Professor Guntram Schernthaner Medical University of Vienna, Austria guntram.schernthaner@meduniwien.ac.at Agenda Glucose
More informationThe place of bariatric surgery in NASH: can we extend the indications? - No
The place of bariatric surgery in NASH: can we extend the indications? - No Nicolas Goossens Service de Gastroentérologie & Hépatologie Hôpitaux Universitaires de Genève Genève, Suisse How to extend the
More informationAdolescent Bariatric Surgery
Adolescent Bariatric Surgery. Roundtable on Obesity Solutions - April 6, 2017 Marc Michalsky, M.D., FACS, FAAP Professor of Clinical Surgery and Pediatrics - The Ohio State University, College of Medicine
More information